Literature DB >> 28584156

Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.

Julien Bador1,2, Catherine Neuwirth3,2, Nadège Grangier1, Marie Muniz1, Leslie Germé1, Jérémy Bonnet1, Vignesh-Guru Pillay1, Catherine Llanes2, Claire de Curraize1,2, Lucie Amoureux1,2.   

Abstract

AxyXY-OprZ is an RND-type efflux system that confers innate aminoglycoside resistance to Achromobacter spp. We investigated here a putative TetR family transcriptional regulator encoded by the axyZ gene located upstream of axyXY-oprZ An in-frame axyZ gene deletion assay led to increased MICs of antibiotic substrates of the efflux system, including aminoglycosides, cefepime, fluoroquinolones, tetracyclines, and erythromycin, indicating that the product of axyZ negatively regulates expression of axyXY-oprZ Moreover, we identified an amino acid substitution at position 29 of AxyZ (V29G) in a clinical Achromobacter strain that occurred during the course of chronic respiratory tract colonization in a cystic fibrosis (CF) patient. This substitution, also detected in three other strains exposed in vitro to tobramycin, led to an increase in the axyY transcription level (5- to 17-fold) together with an increase in antibiotic resistance level. This overproduction of AxyXY-OprZ is the first description of antibiotic resistance acquisition due to modification of a chromosomally encoded mechanism in Achromobacter and might have an impact on the management of infected CF patients. Indeed, tobramycin is widely used for aerosol therapy within this population, and we have demonstrated that it easily selects mutants with increased MICs of not only aminoglycosides but also fluoroquinolones, cefepime, and tetracyclines.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Achromobacter; AxyXY-OprZ; AxyZ; cystic fibrosis; efflux; tobramycin

Mesh:

Substances:

Year:  2017        PMID: 28584156      PMCID: PMC5527583          DOI: 10.1128/AAC.00290-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.

Authors:  Catherine Llanes; Didier Hocquet; Christelle Vogne; Dounia Benali-Baitich; Catherine Neuwirth; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  VIM-2 metallo-beta-lactamase in Achromobacter xylosoxidans in Europe.

Authors:  D Sofianou; A Markogiannakis; E Metzidie; S Pournaras; A Tsakris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

3.  Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product.

Authors:  Yuji Morita; Mara L Sobel; Keith Poole
Journal:  J Bacteriol       Date:  2006-03       Impact factor: 3.490

4.  Achromobacter xylosoxidans n. sp. from human ear discharge.

Authors:  E Yabuuchi; A Oyama
Journal:  Jpn J Microbiol       Date:  1971-09

5.  Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.

Authors:  S Westbrock-Wadman; D R Sherman; M J Hickey; S N Coulter; Y Q Zhu; P Warrener; L Y Nguyen; R M Shawar; K R Folger; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Mapping of the plasmid (pLQ3) from Achromobacter and cloning of its cephalosporinase gene in Escherichia coli.

Authors:  R Levesque; P H Roy
Journal:  Gene       Date:  1982-04       Impact factor: 3.688

7.  Achromobacter insolitus sp. nov. and Achromobacter spanius sp. nov., from human clinical samples.

Authors:  Tom Coenye; Marc Vancanneyt; Enevold Falsen; Jean Swings; Peter Vandamme
Journal:  Int J Syst Evol Microbiol       Date:  2003-11       Impact factor: 2.747

8.  Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Christelle Vogne; Julio Ramos Aires; Christiane Bailly; Didier Hocquet; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates.

Authors:  Lucie Amoureux; Julien Bador; Fatma Bounoua Zouak; Angélique Chapuis; Claire de Curraize; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2016-01-08       Impact factor: 5.482

10.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

View more
  7 in total

1.  Structure, Assembly, and Function of Tripartite Efflux and Type 1 Secretion Systems in Gram-Negative Bacteria.

Authors:  Ilyas Alav; Jessica Kobylka; Miriam S Kuth; Klaas M Pos; Martin Picard; Jessica M A Blair; Vassiliy N Bavro
Journal:  Chem Rev       Date:  2021-04-28       Impact factor: 60.622

Review 2.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

3.  Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans.

Authors:  Frank Fleurbaaij; Alex A Henneman; Jeroen Corver; Cornelis W Knetsch; Wiep Klaas Smits; Sjoerd T Nauta; Martin Giera; Irina Dragan; Nitin Kumar; Trevor D Lawley; Aswin Verhoeven; Hans C van Leeuwen; Ed J Kuijper; Paul J Hensbergen
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

4.  Motility, Biofilm Formation and Antimicrobial Efflux of Sessile and Planktonic Cells of Achromobacter xylosoxidans.

Authors:  Signe M Nielsen; Line N Penstoft; Niels Nørskov-Lauritsen
Journal:  Pathogens       Date:  2019-01-27

5.  Genomic and Phenotypic Evolution of Achromobacter xylosoxidans during Chronic Airway Infections of Patients with Cystic Fibrosis.

Authors:  S M Hossein Khademi; Migle Gabrielaite; Magnus Paulsson; Mattis Knulst; Eleni Touriki; Rasmus L Marvig; Lisa I Påhlman
Journal:  mSystems       Date:  2021-06-29       Impact factor: 6.496

6.  An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics of Achromobacter spp. (Labeled Biochemically or by MAL-DI-TOF MS as A. xylosoxidans), Largely in Patient Groups Other than Those with CF.

Authors:  Claudio Neidhöfer; Christina Berens; Marijo Parčina
Journal:  Antibiotics (Basel)       Date:  2022-02-25

7.  Achromobacter spp. genetic adaptation in cystic fibrosis.

Authors:  Migle Gabrielaite; Finn C Nielsen; Helle K Johansen; Rasmus L Marvig
Journal:  Microb Genom       Date:  2021-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.